ThermoMind is a pioneering technology in the health care industry, founded in 2022 and based in Israel. The company's slogan, "Next Generation Multimodal Screening Modality," captures its core mission. ThermoMind's advanced approach combines Dynamic Multimodal Imaging and artificial intelligence to immediately detect and track biomarkers related to metabolic abnormalities caused by cancer cells. This innovative technology has recently attracted substantial investment, with a €11.43M grant investment received on 05 August 2022. The latest funding round signifies a strong endorsement of ThermoMind's potential to revolutionize cancer screening and diagnosis.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Grant | €11.43M | - | 05 Aug 2022 |
No recent news or press coverage available for ThermoMind.